RT Journal Article
SR Electronic
T1 PO.6.137 Design of a phase 2, multicenter, randomized, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of nipocalimab in adults with active systemic lupus erythematosus
JF Lupus Science & Medicine
JO Lupus Sci Med
FD Lupus Foundation of America
SP A104
OP A105
DO 10.1136/lupus-2022-elm2022.158
VO 9
IS Suppl 2
A1 Liu-Walsh, F
A1 Van Hartingsveldt, B
A1 Zuraw, Q
A1 Hoffman, RW
A1 Rooney, T
A1 Gao, S
A1 Gordon, R
A1 Leu, JH
A1 Berhanu Debella, A
A1 Calderon, C
A1 Zazzetti, F
A1 Vratsanos, G
YR 2022
UL http://lupus.bmj.com/content/9/Suppl_2/A104.2.abstract
AB Objective Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease characterized by pathogenic autoantibodies and tissue damage to multiple organ systems. Approved treatments are few and associated with limitations including suboptimal response for many patients. Nipocalimab is a novel high affinity, fully human, aglycosylated, effectorless IgG1 monoclonal antibody that selectively targets the neonatal Fc receptor (FcRn). Clinical studies conducted with nipocalimab in healthy volunteers (NCT02828046) and in adult generalized myasthenia gravis patients (NCT03896295) demonstrated rapid and durable serum IgG and pathogenic autoantibody reductions, which may be therapeutic across a broad range of autoantibody-mediated immune disorders including SLE. This abstract describes the protocol of a Phase 2 study evaluating efficacy and safety of nipocalimab in patients with active SLE (NCT04882878).Methods This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study enrolling adults with active, autoantibody-positive SLE with an inadequate response to ≥1 standard of care (SoC) treatments. The study consists of a ≤6-week screening period, a 52-week double-blind treatment period, and a 6-week follow-up period (figure 1). Approximately 225 participants will be randomized in a 1:1:1 ratio to receive nipocalimab dose 1, dose 2 or placebo intravenously every 2 weeks through Week 50.Results The primary efficacy endpoint is the percentage of participants achieving an SLE Responder Index (SRI)-4 composite response at Week 24. Secondary efficacy endpoints assessed at Week 24 include the percentage of participants achieving: ≥50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity score (CLASI), ≥50% reduction in active joints, ≥4 points improvement in SLE Disease Activity Index 2000 (SLEDAI 2K), and British Isles Lupus Assessment Group Composite Lupus Assessment response (BICLA); time to first disease flare; and reduction in corticosteroid use. Percentage of participants achieving an SRI-4 composite response at Week 52 will also be assessed. Safety endpoints include adverse events (AEs), serious AEs, AEs of special interest (severe infections, grade ≥3 hypoalbuminemia), and AEs leading to treatment discontinuation through Week 58.Abstract PO.6.137 Figure 1 Study designConclusion This ongoing phase 2 study will evaluate the safety and efficacy of nipocalimab in adults with active SLE, using multiple clinical outcome measures.